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1069-120 Improved One-Year Survival of Hospitalized Heart 
Failure Patients Between 1995 and 2000
Eyal Shahar, Seungmin Lee, Joseph Kim, Sue Duval, Cheryl Barber, Russell V. Luepker, 
University of Minnesota, Minneapolis, MN
Background: Few studies have examined population-based secular trends in survival of
patients with congestive heart failure (CHF).
Methods: We obtained lists of discharge diagnosis codes in 1995, and again in 2000,
from 22 Minneapolis-St. Paul hospitals; identified patients 35-79 years old with a CHF
discharge code; and reviewed a sample of the records (50% of 1995 records; 38% of
2000 records). To identify CHF-related hospitalizations, we applied six published defini-
tions of the syndrome to each record and selected patients whose records met at least
four of these six definitions (2,257 patients in 1995; 1,825 patients in 2000). Each patient
was followed for one year to ascertain vital status.
Results: The risk profile of the 2000 patient cohort was somewhat worse than that of the
1995 cohort in both sex groups. For example, previous diagnoses of CHF, coronary dis-
ease, hypertension, and diabetes were noted more frequently among patients hospital-
ized in 2000, particularly among women. The distributions of age and left ventricular
ejection fraction were similar in the two cohorts. Within one year of admission in 2000,
28% of male patients and 27% of female patients have died, compared to 36% and 27%
of their counterparts in 1995, respectively. Cumulative mortality, adjusted for age and his-
tory of CHF, is shown in the figure.
Conclusions: Survival of patients who were hospitalized for CHF has improved during
the second half of the 1990s, more notably of male patients than of female patients. 
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1070-103 Effect of Aromatase Inhibition on Lipids and 
Inflammatory Markers of Cardiovascular Disease in 
Elderly Hypogonadal Men: A Double-Blind Placebo-
Controlled Randomized Trial
Ryan Dougherty, Jacqueline L. Rohrer, Douglas Hayden, Benjamin Z. Leder, 
Massachusetts General Hospital, Boston, MA
Background: Androgen replacement in elderly men with declining testosterone (T) lev-
els is an increasingly common, though controversial, practice. Recently, aromatase inhib-
itors have been proposed as a novel method of increasing endogenous T production in
elderly men but the effects on lipids and cardiovascular risk have not been defined.
Methods: We randomized 37 hypogonadal men between the ages of 62-74 and T levels
between 150-350 ng/dL to receive oral anastrozole (a potent aromatase inhibitor) 1mg
daily, 1mg twice weekly, or placebo for 12 weeks. Serum levels of fasting lipids, C-reac-
tive protein (CRP), interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), vas-
cular cell adhesion molecule-1 (VCAM-1), and insulin sensitivity were assessed.
Results: Anastrozole normalized testosterone and decreased estradiol levels modestly
at both doses. This intervention had no effect on fasting lipids, inflammatory markers (IL-
6, CRP), adhesion molecules (ICAM-1, VCAM-1), or insulin sensitivity (homeostasis
model assessment). There was, however, a significant positive correlation between
changes in serum triglyceride and estradiol levels (p=0.005). 
Conclusion: Short-term use of the aromatase inhibitor anastrozole normalizes serum 
testosterone levels in elderly men with mild hypogonadism without adversely affecting lip-
ids, inflammatory markers, or insulin resistance. Further studies are needed to assess 
the long-term effects of aromatase inhibitors on cardiovascular health.
1070-104 Age-Related Complications and Outcomes After 
Primary Percutaneous Coronary Interventions
Rajendra H. Mehta, Kishore J. Harjai, Judy Boura, Simon Dixon, Cindy L. Grines, William 
O'Neill, University of Michigan, Ann Arbor, MI, William Beaumont Hospital, Royal Oak, MI
Background: Prior investigations have shown that advancing age is associated with
increased comorbid conditions and is an independent predictor of mortality in patients
with acute myocardial infarction. However, the relationship of age to in-hospital complica-
tions and outcomes in patients undergoing primary percutaneous coronary intervention
(PCI) is less known. Methods: We evaluated 2454 consecutive patients that underwent
primary PCI between 1991 through 2002 at William Beaumont Hospital. Patients were
characterized into 3 age-based groups (<50, 50-69 and >70 years). Results: In-hospital
complications are as shown in table. No patient age <50 years died in hospital, whereas
mortality occurred in 12 (1%) and 36 (4%) of patients aged 50-<70 years and >70 years,
respectively (p<0.0001). Conclusions: Our data indicates that many in-hospital compli-
cations are increased with aging in patients undergoing primary PCI. This increased
complication rates may, in addition to the increased comorbid conditions, contribute to
the higher mortality observed with advancing age.
Changes in Serum Markers (mean ± SD)
Testostero
ne (ng/dL)
Estradio
l (pg/mL)
High Density 
Lipoprotein 
(mg/dL)
CRP 
(mg/
L)
ICAM-1 
(ng/mL)
Anastrozole 
1mg QD 
(n=12)
Baseline 343 ± 61 26 ± 8 54 ± 11 2.3 ± 
2.7
265 ± 
82
Week 12 572 ± 139* 17 ± 6* 51 ± 10 2.1 ± 
2.0
259 ± 
72
Anastrozole 
1 mg 2x/wk 
(n=11)
Baseline 397 ± 106 27 ± 8 49 ± 12 1.8 ± 
2.2
227 ± 
49
Week 12 520 ± 91* 17 ± 5* 45 ± 12 1.7 ± 
1.7
219 ± 
45
Placebo
(n=14)
Baseline 344 ± 76 23 ± 4 50 ± 16 1.8 ± 
2.6
254 ± 
58
Week 12 344 ± 85 25 ± 6 47 ± 15 1.5 ± 
1.3
244 ± 
52
*p<0.001 compared to placebo
In-hospital complications
Complications Age<50 yrs Age 50-<70 
yrs
Age >/=70 
yrs
p-value
N 342 1231 881
Intubation 0% 0.9% 1.4% 0.08
Intraaortic balloon pump 4.7% 7.2% 7.6 0.18
New shock 0 0.5 0.5 0.62
Coronary perforation 0 0.6 0.5 0.54
Abrupt closure 0.3 0.7 0.5 0.54
No-reflow 1.5 2.2 2.5 0.54
Urgent CABG 0.9 1.6 1.7 0.55
Groin hematoma 12 16 24 <0.001
Retroperitoneal bleed 0 0.1 0.8 0.08
Major bleeding requiring 
transfusion
0 4.4 11.3 <0.001
Reinfarction 0.9 1.7 2.0 0.37
Renal failure 1.2 1.4 4.5 <0.001
Need for Dialysis 0.6 0.2 1.3 0.007
Stroke 0.3 0.2 0.9 0.037
Length of stay (mean [SD], days) 3.3 (2.4) 4.6 (13) 6.6 (14) <0.001
